Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins Sells 5,000 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total value of $244,000.00. Following the sale, the director now directly owns 31,471 shares of the company’s stock, valued at $1,535,784.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ:AMPH opened at $45.48 on Thursday. The firm has a market cap of $2.19 billion, a PE ratio of 15.16, a price-to-earnings-growth ratio of 0.92 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The firm’s fifty day moving average is $48.42 and its 200-day moving average is $44.34. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AMPH. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $63.00.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc lifted its stake in shares of Amphastar Pharmaceuticals by 67.4% in the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock worth $67,663,000 after acquiring an additional 680,976 shares during the period. Epoch Investment Partners Inc. lifted its position in shares of Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock worth $43,154,000 after purchasing an additional 280,390 shares during the period. American Century Companies Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 19.7% in the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock valued at $29,616,000 after purchasing an additional 121,764 shares during the last quarter. Millennium Management LLC increased its position in shares of Amphastar Pharmaceuticals by 84.6% during the second quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock worth $29,550,000 after buying an additional 338,653 shares during the period. Finally, Boston Trust Walden Corp bought a new position in Amphastar Pharmaceuticals during the third quarter worth $26,189,000. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.